Aura Biosciences, Inc. (AURA) - Long-Term Debt to Capital

Aura Biosciences, Inc. (AURA) lacks a sustainable cash flow, as all resources are invested in scientific research, rendering operational activities unstable. The primary growth catalyst will be the upcoming final trials of drugs targeting rare eye tumors, with the current metric standing at 0.04. This price chart complements the profile of the biotech firm developing viral therapy to preserve patient vision.

This ratio measures the share of long-term borrowings within the equity structure, determining the degree of financial leverage and the company's reliance on external credit for long-term planning. An analysis of the long-term debt-to-equity ratio for Aura Biosciences, Inc. (AURA) confirms the resilience of the model, where patent protection of oncology platforms and FDA support minimize default risks even amidst high clinical trial expenditures.